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Abstract
Objective: Stereotactic body radiotherapy (SBRT) has been shown to improve overall survival in patients with
advanced hepatocellular carcinoma. This study aimed to assess the cost-effectiveness of SBRT compared to
sorafenib which is the only drug for advanced hepatocellular carcinoma.
Methods: A Markov decision-analytic model was performed to compare the cost-effectiveness of SBRT and sorafenib
for unresectable advanced hepatocellular carcinoma. Patients transitioned between three health states: stable disease,
progression disease and death. We calculated the data on cost from the perspective of our National Health Insurance
Bureau. Sensitivity analyses were conducted to determine the impact of several variables.
Results: The incremental cost effectiveness ratio (ICER) for sorafenib compared to SBRT was NT$3,788,238 per
quality-adjusted life year gained (cost/QALY), which was higher than the willingness to pay threshold of Taiwan
according to WHO’s guideline. One-way sensitivity analysis revealed that the utility of progression disease for the
sorafenib treatment, utility of progression free survival for SBRT, utility of progression free survival for sorafenib,
utility of PFS to progression disease for SBRT and transition probability of progression disease to dead for SBRT
were the most sensitive parameters in all cost scenarios. The Monte-Carlo simulation demonstrated that the
probability of cost-effectiveness at a willingness to pay threshold of NT$ 2,213,145 per QALY was 100 % and 0 %
chance for SBRT and sorafenib.
Conclusion: This study indicated that SBRT for advanced hepatocellular carcinoma is cost-effective at a willingness to
pay threshold as defined by WHO guideline in Taiwan.
Keywords: Cost-effectiveness analysis, ICER, Advanced hepatocellular carcinoma, Sorafenib
Background
Hepatocellular carcinoma (HCC) is the second leading
cause of cancer death worldwide and Taiwan in 2012
and 2014, respectively [1, 2]. The incidence and mortal-
ity of HCC has continuously increased globally in
North America and Asian countries [3–5]. The in-
creased incidence of HCC is correlated with the high
prevalence of cirrhosis hepatitis C virus, which did not
have any vaccine for prevention [6]. HCC can be
treated with surgical resection, radiofrequency ablation
(RFA), transarterial chemoembolization (TACE) or liver
transplantation if diagnosed early [7, 8]. However, the
majority of HCC patients are diagnosed at an advanced
stage with poor liver function, a significant proportion
of patients are incurable, with median survival rate are
generally 1-year ranging from 20 to 30 % [9–11]. In pa-
tients with un-resectable HCC and contraindicated
TACE, sorafenib is the only option that can increase 1-
year survival to 45 %, particularly effective in patients
with limiting extrahepatic spread [12, 13]. As the ad-
vances in technology of radiation planning and imaging,
Stereotactic body radiotherapy (SBRT) is a radiation
technique which deliver a higher radiation dose in few
fractions to target lesions with low doses to the nonin-
volved liver. Therefore it has become a feasible and safe
modern technique for patients with localized HCC and
* Correspondence: agnes.lf@gmail.com
4Department of Pharmacy, An-Nan Hospital, China Medical University, 1. No.
66, Sec. 2, Changhe Rd., Annan Dist., Tainan, Taiwan
Full list of author information is available at the end of the article
© 2016 Leung et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Leung et al. Radiation Oncology  (2016) 11:69 
DOI 10.1186/s13014-016-0644-4
not eligible to TACE [14]. The radiation-induced liver
disease (RILD) rates were less than 5 % [15]. Over the
past decades, many studies have suggested that SBRT
can be used safely with local control rates of 75 to
100 % at 1 to 2 years survival [14, 16–18]. Recently, the
phase I and the subsequent phase II trial reported that
SBRT improved the median overall survival about
17 months [16].
Although sorafenib and SBRT has showed an improve-
ment in the median overall survival for the treatment of
advanced HCC, the financial burden for its use are sub-
stantial. As the one payer healthcare system in our coun-
try, the healthcare expenditures have become one of the
most important issues from the perspective of healthcare
provider. This study was intended to compare whether




A systematic literature search of the PubMed database
was performed to identify all randomized controlled
trials (RCT) of sorafenib or SBRT for unresectable he-
patocellular carcinoma from January 1, 1999, to March
31, 2016. The search strategy was based on combina-
tions of (“unresectable” or “inoperable” or “advanced”
or “metastatic” hepatocellular carcinoma” [Mesh]) and
(SBRT or sorafenib [Mesh] (“randomized controlled tri-
als” or” clinical trials” [Mesh]). We also searched cost-
effectiveness studies using the medical subject headings
or text key words: quality-adjusted, QALY, life-year
gained (LYG) and cost-effectiveness. The appropriate
full text was reviewed and evaluated by 2 reviewers (AC
and HL) independently, using the same inclusion and
exclusion criteria. RCT or clinical studies published in
English that evaluated sorafenib or SBRT for mHCC
were included. Letters to the editor, case reports, non
randomized trials, animal studies, editorials and posters
were excluded. Any discrepancies in inclusion were re-
solved by consensus. We finally selected one RCT and
one clinical trial of sorafenib and SBRT for advanced
hepatocellular carcinoma as the clinical data source of
the model.
Markov model
The decision-analytic Markov model comparing the
cost-effectiveness of two different regimens over a 5-
year time horizon was programmed in TreeAge Pro
2014 Suite (R1.0 Released; TreeAge Inc., Williamstown,
MA). The clinical data of population modeled, adverse
events and treatment protocol were based on the
SHARP and Phase I/II clinical trials [12, 16]. As the ex-
perts’ opinion and referred to the published literature,
three health states were considered in the model: stable
disease, progression disease and death for inoperable
advanced HCC (Fig. 1). A patient in the model was
considered to be in one of three health states at any
time. All patients began from the stable stage and tran-
sit from one state to another on the basis of the transi-
tion probabilities and received either sorafenib or SBRT
according to the treatment regimen. All parameters
were detailed in Table 1. Our model did not include
deaths from natural causes occurring in any health
state. Death from cancer was assumed to happen after
disease progression. The model perspective was based
on that of the National Health Insurance (NHI) in
Taiwan, with a 1-month cycle length and adjusted to
half-cycle in each health state process. The model time
horizon was set to 5 years to avoid the exclusion of
long-term survivors. All costs and health outcomes
were discounted at a real annual rate of 3 % to adjust
for the relative value of the Taiwan dollar at present.
We used the definition of willingness to pay (WTP)
threshold suggested by the World Health Organization
(WHO): 3 times the per capita gross domestic product
(GDP) [19, 20]. The Taiwan per capita GDP in 2015
was $ NT$737,715 (US$22,355) [21]; thus, a WTP
threshold was considered as $ NT2,213,145/QALY. The
outcomes of the analysis are expressed as incremental
costs effectiveness ratio (ICER) which was the costs
spent to gain a quality adjusted life-years (QALY).
Model parameters were described in Table 1. A panel
of local experts (blood oncologist and radiation oncologist
and one expert in economic evaluations) was consulted to
ensure that assumptions taken into consideration in the
model reflected routine clinical practice.
Treatment regimen
The outcome data from the SHARP and Phase I/II clin-
ical trial were used [12, 16]. As expert opinions, the total
radiation dose, sorafenib dose and schedule, patterns of
treatment failure and survival of the regimen were as-
sumed to be the same as those in the trials. According
Fig. 1 The decision-analytic, Markov model schema. PFS, progression
free survival
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to the SHARP trial, patients were randomized to receive
continuous sorafenib oral treatment with either 400 mg
of sorafenib (consisting of two 200-mg tablets) twice
daily for 6 week cycles. Tumor measurements were per-
formed at screening, every 6 weeks during treatment
(within 10 days before the end of each cycle), and at the
end of treatment by computed tomography or magnetic
resonance imaging. Patients visited the clinic every
3 weeks and at the end of treatment for assessment of
compliance, safety, and determination of side effects.
The SBRT treatment regimen was according to the
phase I/II trial, doses of 30 to 54 Gy (24 to 54 Gy in
Trial 1) in six fractions every other day over 2 weeks
were delivered to the planning target volume (PTV).
The dose to tumor vascular thrombosis plus PTV mar-
gin could be limited to 30 Gy. Detailed description was
in the trial [16].
Probabilities and utilities
Key probabilities for this model were included in
Table 1. The trial did not collect probabilities and util-
ity weights, therefore, the utilities were necessary to
retrieve from the published literature [17, 18]. Transi-
tion probabilities of health states were estimated as
follows: P(1 month) = 1- (0.5) (1/median PFS); this equation
was derived from the following equations: P = 1 − e−
RandR = − ln〔0.5〕/1 − (0.5)(1/median time)/number of treat-
ment cycles) [22, 23]. The efficacies of sorafenib and SBRT
treatment were extracted by Kaplan-Meier survival
curves of the patients whose data were collected from
two clinical trials.
Medical costs
The direct medical costs in this study were extracted
from the National Health Insurance research database
(NHIRD) and converted to 2015 NT dollar (1US$ = NT$
33.0).The direct medical cost in this study included drug
costs, laboratory test, physician visits, pharmacy dispens-
ing fee, administration and nursing care fee. The drug
costs for sorafenib and the costs of treatments for grade
3/4 adverse events (AE) were also included (Table 2). As
a policy issued by the NHI, the reimbursement cost of
SBRT is about NT$210,000 as a treatment package for
early hepatocellular carcinoma and lung cancer, we
therefore assumed this reimbursement cost for advanced
HCC. We also assumed that the patient who survived by
additional 1 month may produce the additional costs of
visiting outpatient monthly.
Sensitivity analysis
One-way sensitivity analysis was conducted to deter-
mine the potential impact of different parameters on
this analysis; the result was presented as a tornado dia-
gram. We hypothesized that the parameters varied over
a range of ± 30 % in relation to its base-case value
(Table 1).
The probabilistic sensitivity analysis using a Monte
Carlo simulation was conducted to assess the impact of
the uncertainty around the key parameters of the model
Table 1 Base-case values and ranges used in sensitivity analyses (± 30 %)
Parameters Base estimate Lower Limit- Upper Limit Assumed distribution
Transition Probability
PFS for sorafenib 0.1533 0.1073–0.1993 Beta
PFS To PD for sorafenib 0.0627 0.044–0.082 Beta
PD To death for sorafenib 0.1184 0.063–0.154 Beta
PFS for SBRT 0.086 0.061–0.034 Beta
PFS To PD for SBRT 0.109 0.076–0.142 Beta
PD To death for SBRT 0.0399 0.028–0.052 Beta
Utility
PFS for sorafenib 0.76 0.546–1.014 Beta
PD for sorafenib 0.68 0.476–0.806 Beta
PFS for SBRT 0.72 0.504–0.936 Beta
PD for SBRT 0.63 0.441–0.819 Beta
Direct Medical Costs (US$ = 33 NT)
cPFS for sorafenib 563365 394355–732375 Constant
cPFS for SBRT 259056 181339–336773 Constant
cPD for sorafenib 417528 292270–542786 Constant
cPD for SBRT 417528 292270–542786 Constant
Abbreviations: c cost, SBRT sterotactic body radiation therapy, PFS progression free survival, PD progression disease
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on the ICER. That is, distributions for each parameter
with the probabilistic sensitivity analysis were modeled.
Log-normal distributions were adopted for all costs and
beta distributions were adopted for probabilities, utilities
and toxicity. The probabilistic sensitivity analysis was
based on 10,000 samples, and the results were presented
as a cost-effectiveness acceptability curve.
Toxicity
We considered only grade 3–4 toxicity associated with
sorafenib or SBRT as the two clinical trials. The rate of
drug-related severe toxicity caused permanent treatment
and discontinuation of the drug was 11 % for sorafenib
and 24.8 % for SBRT [12, 16].
Results
Patient baseline characteristics
The baseline characteristics of the patients treated with
sorafenib or SBRT were well balanced and no significant
differences were noted with respect to sex, age, ECOG
performance status, plasma levels of α-fetoprotein (AFP),
Barcelona Clinic Liver Cancer staging B and C. However,
the percentage of Child-Pugh class A liver function, extra-
hepatic spread and vascular invasion were higher in
SHARP trial compared to the Phase I/II trial (Table 3).
Direct medical costs
The direct medical costs of the drugs, laboratory test,
physician visits, pharmacy dispensing fee, administration,
nursing care fee and grade 3/4 AE treatments were
shown in Table 2.
Effectiveness
The median overall survival (mOS) and median time to
progression (mTTP) were 10.7 and 4.1 months in the so-
rafenib group of the SHARP trial, whereas, the mOS and
mTPP were 17 and 6.0 months in the SBRT group from
the Phase I/II trials, as shown in the Kaplan-Meier sur-
vival curves (Fig. 2). According to the equation described
above, the monthly transition probability for PFS state
was 0.153, from PFS to progression disease (PD) state
was 0.0627, from PD state to death was 0.1184 for the
sorafenib group. For SBRT, the monthly transition prob-
ability for PFS state was 0.086, from PFS to progression
disease (PD) state was 0.109, from PD state to death was
0.0399 (Table 1). Utility scores of the health states were
retrieved from two previously published studies (sorafe-
nib group: 0.68 for PD, 0.76 for PFS; SBRT group: 0.63
for PD1, 0.72 for PFS1) [24, 25].
Base-case analysis
The cost-effectiveness analysis demonstrated that the
ICER for sorafenib compared to SBRT was NT$
3,788,238 per quality-adjusted life year gained (cost/
QALY) in the base scenario. Based on the WTP thresh-
old of NT$ 2,213,145/QALY, the sorafenib was not
cost-effective versus SBRT under the defined WTP
threshold in this analysis (Table 4).
Sensitivity analyses
One-way sensitivity analysis was done for SBRT and
sorafenib with a hypothesized variation of ±30 % in pa-
tients treated with two regimens by using the tornado
diagram. The results showed the important parameters
driving the model. The broader the horizontal bar in a
tornado diagram, the more impact the input parameter
Table 2 Estimated cost inputs used in the model
Cost input Value
Cost administration and health States
PFS per course
Sorafenib SBRT
Drug or treatment cost 537,264 210,000
Costs of test: laboratory test, CT 21,000 32,347
Costs of physician visit, dispensing fee, nursing care 3000 0
Adverse events treatment 38 16709
Sub-total 563,365 259,056
PD per visit
Costs of test: laboratory test, CT 10,728 10,728
Costs of physician visit, dispensing fee, nursing care 15,600 15,600
End of life care 391,200 391,200
Sub-total 417,528 417,528
Abbreviation: PFS progression free survival, PD progression disease, CT computerized tomography, SBRT stereotactic body radiotherapy
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has on the model. Analyses showed that the results of
the model were highly sensitive to an assumption on the
first five parameters, which were utility of progression
disease for the sorafenib treatment, utility of progression
free survival for SBRT, utility of progression free survival
for sorafenib, utility of PFS to progression disease for
SBRT and transition probability of progression disease to
dead for SBRT (Fig. 3).
Probabilistic sensitivity analyze
Varying all variables simultaneously by ± 30 % in the
Monte Carlo simulation, the results demonstrated that
the probability of cost-effectiveness at a willingness to
pay threshold of NT$ 2,213,145 per QALY was 100 %
and 0 % chance for SBRT and sorafenib (Fig. 4).
Discussion
Sorafenib is currently used as the most effective option
for patients with advanced un-resectable HCC and for
those contraindicated to TACE [12]. The median over-
all survival of patients treated with sorafenib was
10.7 months. Most of the economic evaluation on so-
rafenib in unresectable HCC was cost-effective com-
pared to best supportive care conducted in the USA
[26, 27]. However, it was not a cost-effective option for
patients with advanced HCC from the societal perspec-
tive in China [25]. Due to advances in radiotherapy
planning and imaging technologies, SBRT have been
suggested to be used safely for localized or unresectable
advanced HCC with local control rate of 75–100 % at 1
to 2 years. Additionally, SBRT may provide better
Table 3 Baseline characteristics of the patients in the sharp and phase I/II trial
Characteristics SHARP trial Phase I/II trial P value
Age, years 64.9 69.4 0.22
Male no (%) 260 (87 %) 80 (78.4 %) 0.244
Underlying liver disease 0.011
Hepatitis B 56 (19 %) 39 (38.2 %)
Hepatitis C 87 (29) 39 (38.2 %)
Alcohol related 79 (26 %) 25 (24.5 %)
Other 28 (9 %) 14 (13.7 %)
Unkown 49 (16 %) 7 (6.9)
ECOG performance status n (%) 0.225
0 161 (54 %) 85 (83.3)
1 114 (38 %)
2 24 (8 %) 11 (10.8 %)
BCLC stage 0.208
B (intermediate) 54 (18 %) 35 (34.3 %)
C (advanced) 244 (82 %) 67 (65.7 %)
Child-Pugh class, no (%) < 0.0001
A 284 (95 %) 102 (100 %)
B 14 (5 %) 0 %
Biochemical analysis 0.25
Albumin (g/dl) 3.9 4.0
Total bilirubin (mg/dl) 0.7 1.3
Alpha-fetoprotein 44.3 ng/ml 163 nmol/L
Previous therapy 0.079
Surgery 57 (19 %) 9 (8.8 %)
TACE 86 (29 %) 22 (21.6 %)
RFA 17 (6 %) 35 (34.3 %)
PEI 28 (9 %) 16 (15.7 %)
Extrahepatic spread (no,%) 159 (53 %) 12 (11.8 %) < 0.0001
Vascular invasion (no,%) 108 (36 %) 20 (49 %) < 0.0001
Abbreviations: ECOG Eastern Cooperative Oncology Group, BCLC Barcelona Clinic Liver Cancer staging system, TACE transarterial chemoembolization, RFA
radiofrequency ablation, PEI percutaneous ethanol injection
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quality of life because of more favorable toxicity profile
[16]. As the single payer Healthcare system in Taiwan,
the high drug cost of sorfenib used for treating patients
with advanced HCC have become one of the biggest is-
sues. The decision-maker is probably willing to pay for
less expensive and high outcome treatment for these
patients. The result of this study is probably to provide
the healthcare payer with evidence in determining a
reasonable reimbursement price for the effective treat-
ment strategy for patients with advanced HCC.
In our study, patients in the sorafenib group gained 3.07
QALYs at a cost of NT$ 2,166,079; patients in the SBRT
group gained 2.81 QALYs at a cost of NT$1,197,039. Soraf-
enib increased 0.26 QALYs for these patients but with an
incremental cost of NT$969,041 compared to SBRT. The
ICER in our study was NT$ 3,788,238/QALY(US$114,795/
QALY) for sorafenib versus SBRT treatment, which was
significantly higher than the defined societal willing-
ness to pay threshold in our country (NT$2,213,145/
QALY = US$67,065/QALY) (Table 4). Therefore, soraf-
enib is not a cost-effective treatment for patients with
unresectable advanced HCC in Taiwan. This result is
consistent with the Zhang et al. study conducted in
China because the dose of sorafenib used in their
study was similar to that used by our oncologists in
the field practice [25]. Furthermore, they also used the
same definition of WTP as WHO’s guideline. How-
ever, the ICER in the Zhang et al. study was higher
than that in our study. The reason may be the high
percentage of vascular invasion in the patients col-
lected in their study (macroscopic vascular invasion
was 47.9 % versus ours 36 %, no data available to com-
pare extrahepatic spread), which likely lead to a more
unfavorable outcome in the sorafenib group in terms
of TTP, OS and utility.
The high drug cost of sorafenib may be one of the key
variables that have a great impact on the ICER as com-
pared to placebo or other alternative regimen. The price
of sorafenib reimbursed by the National Health Bureau
was calculated based on the market price and negotiated
with the manufacturer. The difference in the drug cost
and other direct medical cost may result in different
ICER value. On the contrary, SBRT is a cost-effective
option for patients with unresectable advanced HCC
under the assumption of reimbursement in our study.
One-way sensitivity analysis revealed SBRT to be cost-
effective regardless of the variation in any single param-
eter. As our expert opinion, the fixed reimbursement
price of NT$ 210,000 per case may not affect the dose
or technique of SBRT used for either early or unresect-
able advanced HCC. Therefore, from the perspective of
single payer healthcare system, SBRT for the treatment
of unresectable advanced HCC is likely to be cost-
effective compared to sorafenib,
This study has some limitations. First, the perspective
of our study was not societal. Only direct medical costs
were involved, therefore, the costs may be underesti-
mated. Second, our study did not consider dose adjust-
ments (interruptions or reductions), it may have an
impact on ICER value in sorafenib group. Third, the
Fig. 2 Kaplan-Meier Analysis of Overall survival
Table 4 Incremental Cost-Effectiveness Ratios Comparing SBRT
versus sorafenib at the Base Case
Various cost Sorafenib SBRT
QALYs (years) 3.07 2.81
Incremental QALY gained (years) 0.26 -
Lifetime cost (US$) 2166,079.7 1,197,039.2
Incremental cost (NT$) 969,041 -
Cost/effectiveness 704,857.96 426,117.13
ICER (NT$) 3,788,238
Cost-effectiveness threshold (NT$) 2,213,145
Is SBRT cost-effective? No
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percentage of extrahepatic spread in patients of SHARP
trial was higher than that in Phase I/II SBRT trial. This
difference in patient characteristic is likely lead to a
more unfavorable outcome in the sorafenib group in
terms of TTP and OS, thus may have negative impact
on the utility value. Fourth, the percentage of Child-
Pugh class A liver function of patients recruited in
SHARP trial and Phase I/II SBRT trial were 95 and
100 %. As reported by the GIDEON study [28], patients
with advanced HCC with Child-Pugh class A liver func-
tion had a longer OS and TPP than those with Child-
Pugh class B liver function. This difference may slightly
have influence on the utility. However, the uncertainties
associated with these limitations have been estimated
by varying wide ranges of input parameters in sensitiv-
ity analyses and the results are robust.
Fig. 3 Tornado analysis (ICER) for SBRT vs sorafenib. EV, expect value of ICER for gem + IMRT
Fig. 4 Cost-effectiveness acceptability curve. These probability that a specific treatment is cost-effective at a given Willingness-to-pay threshold of
NT 2,213,145 (=US$ 67065, 1 US = 33 NT). SBRT, stereotactic body radiotherapy
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Conclusion
Patients with unresectable advanced HCC within the pa-
tients’ criteria in our study, SBRT is more cost-effective
than sorafenib in Taiwan.
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